The majority pf breast cancers present as ER-positive, many of which are able to be targeted
with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has
the potential to benefit patients by making hormonal therapies a therapeutic option and
possibly improving their overall prognosis.
- Women who have Her-2 positive and ER- negative or ER-low breast cancer that has not
metastasized, or spread to other parts of the body, are eligible for the study.
- Participants must have had either a core biopsy or incisional biopsy of their breast
cancer, but not yet had definitive breast surgery, including lumpectomy or
- Participants may not have had a BRCA mutation found on genetic testing.
- Participants should have not yet received treatment for their breast cancer,
- hormonal therapy,